AI in Drug Discovery Market: Global Trends, Growth Opportunities, and Future Outlook
The AI in Drug Discovery Market is undergoing rapid transformation as pharmaceutical and biotechnology companies increasingly adopt artificial intelligence to improve the speed, efficiency, and accuracy of drug development. According to the latest Market Research Future report, the market was valued at USD 2.81 billion in 2025 and is projected to reach USD 23.95 billion by 2035, expanding at a CAGR of 23.9% between 2026 and 2035.
AI technologies are being applied across multiple stages of drug discovery, including target identification, lead optimization, drug repurposing, preclinical testing, and clinical trials. Machine learning currently represents a major technology segment, while deep learning, natural language processing, knowledge graphs, and robotic process automation are also gaining importance.
The increasing cost and complexity of traditional drug development is a major market driver. AI-powered platforms can analyze large biological and chemical datasets, support virtual screening, predict molecular properties, and help researchers identify promising candidates more efficiently.
North America currently holds the largest regional share, while Asia-Pacific is identified as the fastest-growing region. Pharmaceutical companies, biotechnology firms, research institutions, and academic organizations are adopting AI solutions for drug discovery workflows.
Future opportunities are expected from generative chemistry, foundation models for biology, multi-omics integration, AI-powered rare-disease research, biologics development, and cloud-based AI-as-a-service platforms.